Table 3 Validation studies for association of DEPDC5 with the risk of HCC development among chronic hepatitis patients
From: Main insights of genome wide association studies into HCV-related HCC
Study/year | Ethnicity | Cases/controls | P value | OR(95%CI) |
|---|---|---|---|---|
Motomura 2012 [21] | Japanese | Cohort of 96 HCC hepatectomy patients. | 0.47 | – |
Al-Qahtani 2014 [22] | Saudi | 151 cirrhotic patients + HCC patients/450 Chronic HCV patients. | 0.038 | 1.353 (1.017–1.80) |
Ma 2014 [23] | Chinese | 308 HBV-HCC/373 HBV carriers and 111 cirrhotic patients | HCC VS HBV 0.001 HCC VS cirrhosis 0.009 | HCC VS HBV carriers 1.549 (1.207–1.988) HCC VS cirrhosis 1.837 (1.168–2.902 ) |
Hai 2014 [17] | Japanese | 142 HCV-HCC/575 HCV non-HCC patients | 0.51 | – |
Burza 2016 [14] | Italy, Switzerland, Germany | 192 LC-HCC/199 LC | 0.15 | – |
Liu 2019 [24] | Chinese | 308 HBV-HCC patients/217 chronic HBV, 258 cirrhotic, and 506 healthy controls. | HCC VS healthy controls = 0.015 HCC VS CHB = 0.02 HCC VS LC = 0.004 | HCC VS healthy controls 2.008 (1.145, 3.520) HCC VS CHB 2.241 (1.226–4.461) HCC VS LC 2.706 ( 1.371- 5.340) |